Organon & Co. (OGN)
(Delayed Data from NYSE)
$18.10 USD
+0.10 (0.56%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $18.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.10 USD
+0.10 (0.56%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $18.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth A Momentum B VGM
Zacks News
Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Don't Overlook These Low-Risk High-Dividend Yielding Stocks
by Shaun Pruitt
Now looks like a good time to buy these highly ranked stocks with earnings estimate revisions likely to keep ticking up after their favorable Q4 results which makes their high dividend yields and low beta ratios more attractive.
The Zacks Analyst Blog Highlights Booz Allen Hamilton, Tyson Foods, AXIS Capital, First Financial and Organon
by Zacks Equity Research
Booz Allen Hamilton, Tyson Foods, AXIS Capital, First Financial and Organon are included in this Analyst Blog.
Top 5 Low-Beta High-Yielding Stocks to Shield Your Portfolio
by Nalak Das
We have narrowed our search to five low-beta (beta >0 <1) stocks with a solid dividend yield. These are: BAH, AXS, OGN, TSN, FFIN.
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DES
Is WisdomTree U.S. SmallCap Dividend ETF (DES) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DES
Organon (OGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Viatris (VTRS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Life Time Group Holdings, Inc. (LTH) Q3 Earnings Match Estimates
by Zacks Equity Research
Life Time Group Holdings, Inc. (LTH) delivered earnings and revenue surprises of 0% and 0.16%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Organon (OGN) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Organon (OGN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 35.05% and 3.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Sotera Health Company (SHC) Tops Q2 Earnings Estimates
by Zacks Equity Research
Sotera Health Company (SHC) delivered earnings and revenue surprises of 16.67% and 2.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Organon (OGN) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Organon (OGN) Lags Q1 Earnings Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of -8.47% and 1.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organon (OGN) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of -4.71% and 1.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Organon (OGN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Organon (OGN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 17.86% and 2.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: InnovAge Holding Corp. (INNV) Q1 Earnings Expected to Decline
by Zacks Equity Research
InnovAge Holding Corp. (INNV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is WisdomTree U.S. MidCap ETF (EZM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EZM
Should WisdomTree U.S. MidCap ETF (EZM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for EZM